Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Residual Schizophrenia
NCT ID: NCT02477670
Last Updated: 2020-09-16
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
145 participants
INTERVENTIONAL
2015-09-30
2017-07-21
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Negative Symptoms of Schizophrenia
NCT03896945
Study to Assess Efficacy and Safety of HP3070 in Subjects Diagnosed With Schizophrenia.
NCT02876900
A Phase 2 Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia
NCT01678755
Safety and Efficacy of Study Drug Versus Placebo for Negative Symptoms of Schizophrenia
NCT00063297
Efficacy of NBI-1117568 in Preventing Relapse in Adults With Schizophrenia
NCT07227818
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Placebo
Placebo capsules administered twice a day over a 12-week period
Placebo
AVP-786
AVP-786 dose 2 capsules administered twice a day over a 12-week period
AVP-786
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
AVP-786
Placebo
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients must meet PANSS criteria
* Patients currently receiving atypical antipsychotics are eligible provided they are on a stable dose
Exclusion Criteria
* Patients with extrapyramidal syndrome secondary to their ongoing antipsychotic medication
* Patients currently using anticholinergic medications
* Recent in-patient hospitalization
18 Years
60 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Avanir Pharmaceuticals
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Cerritos, California, United States
Garden Grove, California, United States
National City, California, United States
Oakland, California, United States
San Diego, California, United States
Washington D.C., District of Columbia, United States
Orlando, Florida, United States
Atlanta, Georgia, United States
Augusta, Georgia, United States
Chicago, Illinois, United States
Boston, Massachusetts, United States
Worcester, Massachusetts, United States
Grand Rapids, Michigan, United States
Marlton, New Jersey, United States
Jamaica, New York, United States
New York, New York, United States
Rochester, New York, United States
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Statistical Analysis Plan
Document Type: Study Protocol
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
15-AVP-786-202
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.